Related Experiment Video

Updated: Nov 15, 2025

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.5K

Natural Isoflavones and Semisynthetic Derivatives as Pancreatic Lipase Inhibitors

Nunzio Cardullo1, Vera Muccilli1, Luana Pulvirenti1

  • 1Dipartimento di Scienze Chimiche, Università degli Studi di Catania, V.le A. Doria 6, 95125 Catania, Italy.

Journal of Natural Products
|March 1, 2021
PubMed

Insights

Isoflavones show promise as obesity treatments by inhibiting pancreatic lipase (PL). Genistein and synthetic derivatives, particularly hydroxylated and brominated ones, demonstrated potent PL inhibition, suggesting potential for new anti-obesity agents.

Area of Science:

  • Biochemistry
  • Medicinal Chemistry
  • Pharmacology

Background:

  • Obesity is a global health concern linked to chronic diseases.
  • Orlistat is the sole approved anti-obesity drug, but has side effects.
  • Natural compounds, especially polyphenols, are explored for pancreatic lipase (PL) inhibition.

Purpose of the Study:

  • To investigate the pancreatic lipase inhibitory properties of isoflavones.
  • To evaluate natural isoflavones (daidzein, genistein, formononetin) and their semi-synthetic derivatives.
  • To identify potent isoflavone-based inhibitors for potential anti-obesity applications.

Main Methods:

  • In vitro pancreatic lipase inhibition assays.
  • Fluorescence spectroscopy and enzyme kinetics to study inhibition mechanisms.
  • Molecular docking simulations to understand isoflavone-enzyme interactions.

Main Results:

  • Genistein (2) exhibited significant pancreatic lipase inhibition.
  • Hydroxylated and brominated semi-synthetic isoflavone derivatives showed enhanced potency compared to natural leads.
  • Genistein (2) and brominated derivatives (10, 11) displayed the highest affinity for pancreatic lipase.

Conclusions:

  • Isoflavones, particularly genistein and its modified derivatives, are effective pancreatic lipase inhibitors.
  • Hydroxylation and bromination are beneficial modifications for enhancing isoflavone potency.
  • These findings support the development of novel isoflavone-based anti-obesity therapeutics.

More Related Videos

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.3K
Isolated Pancreatic Islet Treatment and Apoptosis Measurement09:36

Isolated Pancreatic Islet Treatment and Apoptosis Measurement

Published on: May 2, 2025

706

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
570
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
345
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
388
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.1K
Lipid Digestion01:06

Lipid Digestion

Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.
96.8K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
395